NASDAQ:EXAS

Exact Sciences Stock Forecast, Price & News

$125.01

+3.12 (+2.56 %)

(As of 06/14/2021 12:00 AM ET)

Add

Compare

Today's Range

$121.00

▼

$125.96

50-Day Range

$93.66

▼

$139.27

52-Week Range

$70.75

▼

$159.54

Volume1.16 million shs

Average Volume1.68 million shs

Market Capitalization$21.45 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.29

30 days | 90 days | 365 days | Advanced Chart

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Exact Sciences Co. (NASDAQ:EXAS) Receives Consensus Recommendation of "Buy" from Analysts
June 12, 2021 | americanbankingnews.com

Bullish Two Hundred Day Moving Average Cross - EXAS
June 9, 2021 | nasdaq.com

Cramer Gives His Opinion On Novavax, Exact Sciences And More
June 8, 2021 | markets.businessinsider.com

Exact Sciences Technical Correction Is Now Behind Us
June 8, 2021 | finance.yahoo.com

Exact Sciences (NASDAQ:EXAS) vs. AIkido Pharma (NASDAQ:AIKI) Financial Comparison
June 5, 2021 | americanbankingnews.com

EXAS Jun 2021 103.000 put
June 5, 2021 | in.finance.yahoo.com

Exact Sciences (EXAS) Down 1.4% Since Last Earnings Report: Can It Rebound?
June 3, 2021 | finance.yahoo.com

The Goldman Sachs Group Initiates Coverage on Exact Sciences (NASDAQ:EXAS)
June 3, 2021 | americanbankingnews.com

Exact Sciences (NASDAQ:EXAS) and AIkido Pharma (NASDAQ:AIKI) Head to Head Survey
May 26, 2021 | americanbankingnews.com

Exact Sciences (EXAS) Reveals Promising Data on Cologuard
May 26, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXAS
Previous Symbol
CUSIP30063P10
CIK1124140
Webwww.exactsciences.com
Phone608-535-8815
Employees5,000
Year Founded1995

Sales & Book Value

Annual Sales$1.49 billion
Price / Sales14.38
Cash Flow$1.62 per share
Price / Cash Flow77.26
Book Value$18.77 per share
Price / Book6.66

Profitability

EPS (Most Recent Fiscal Year)($1.38)
Net Income$-848,530,000.00
Net Margins-50.08%
Return on Equity-6.55%
Return on Assets-3.62%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares171,551,000
Market Cap$21.45 billion
Next Earnings Date7/29/2021 (Estimated)
OptionableOptionable

Social Links

MarketRank^™

Overall MarketRank^™

1.75 out of 5 stars

Medical Sector

232nd out of 2,100 stocks

Commercial Physical Research Industry

2nd out of 37 stocks

3.4 Analyst's Opinion

Consensus Rating
Exact Sciences has received a consensus rating of Buy. The company's average rating score is 2.76, and is based on 13 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $152.24, Exact Sciences has a forecasted upside of 21.8% from its current price of $125.01.
Amount of Analyst Coverage
Exact Sciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.1 Community Rank

Outperform Votes
Exact Sciences has received 903 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Exact Sciences has received 569 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Exact Sciences has received 61.35% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Exact Sciences and other stocks. Vote “Outperform” if you believe EXAS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EXAS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Exact Sciences does not currently pay a dividend.
Dividend Growth
Exact Sciences does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,176,172.00 in company stock.
Percentage Held by Insiders
Only 1.40% of the stock of Exact Sciences is held by insiders.
Percentage Held by Institutions
88.07% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Exact Sciences are expected to grow in the coming year, from ($2.65) to ($2.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Exact Sciences is -24.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Exact Sciences is -24.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Exact Sciences has a P/B Ratio of 6.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Exact Sciences (NASDAQ:EXAS) Frequently Asked Questions

Is Exact Sciences a buy right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Exact Sciences stock.
View analyst ratings for Exact Sciences or view top-rated stocks.

What stocks does MarketBeat like better than Exact Sciences?

Wall Street analysts have given Exact Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Exact Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Exact Sciences' next earnings date?

Exact Sciences is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Exact Sciences.

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) announced its quarterly earnings data on Monday, May, 3rd. The medical research company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.86. The medical research company had revenue of $402.10 million for the quarter, compared to analyst estimates of $394.66 million. Exact Sciences had a negative net margin of 50.08% and a negative trailing twelve-month return on equity of 6.55%. The firm's revenue was up 15.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.71) earnings per share.
View Exact Sciences' earnings history.

How has Exact Sciences' stock price been impacted by Coronavirus?

Exact Sciences' stock was trading at $57.82 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EXAS shares have increased by 116.2% and is now trading at $125.01.
View which stocks have been most impacted by COVID-19.

What guidance has Exact Sciences issued on next quarter's earnings?

Exact Sciences issued an update on its FY 2021 earnings guidance on Tuesday, May, 18th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $1.69 billion-$1.74 billion, compared to the consensus revenue estimate of $1.72 billion.

What price target have analysts set for EXAS?

17 equities research analysts have issued 1 year price objectives for Exact Sciences' stock. Their forecasts range from $115.00 to $180.00. On average, they expect Exact Sciences' stock price to reach $152.24 in the next twelve months. This suggests a possible upside of 21.8% from the stock's current price.
View analysts' price targets for Exact Sciences or view top-rated stocks among Wall Street analysts.

What are Wall Street analysts saying about Exact Sciences stock?

Here are some recent quotes from research analysts about Exact Sciences stock:

1. The Goldman Sachs Group, Inc. analysts commented, " (6/3/2021)
2. According to Zacks Investment Research, "Exact Sciences’ rising expenses and operating loss are concerning. This created a bottom-line pressure, resulting in net loss in the fourth quarter 2020. The company has not provided any outlook for 2021 on lack of visibility. Its expectations of a fall in COVID-19-testing revenues raise apprehensions. Sole reliance on Cologuard and stiff competition persist. Yet, robust top-line growth in the fourth quarter amid pandemic-led headwinds is impressive. Screening arm’s revenues, driven by Cologuard volume growth during the quarter, is encouraging. Ongoing recovery in precision oncology arm buoys optimism. Gross margin expansion and tie-ups bode well. A strong solvency position is impressive. Over the past six months, Exact Sciences has outperformed its industry." (4/20/2021)

Who are Exact Sciences' key executives?

Exact Sciences' management team includes the following people:

Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 55, Pay $1.92M)
Mr. Jeffrey T. Elliott CFA, Exec. VP, CFO & COO (Age 43, Pay $847.38k)
Mr. D. Scott Coward, Chief Admin. Officer, Exec. VP, Gen. Counsel & Sec. (Age 56, Pay $826.6k)
Mr. Graham P. Lidgard, Emeritus Chief Science Officer (Age 72, Pay $852.84k)
Mr. Jake Orville, Gen. Mang. of Pipeline (Age 47, Pay $651.43k)
Mr. Gary Frings, Chief Information Officer
Dr. Scott C. Johnson Ph.D., Chief Science Officer and Sr. VP of R&D
Ms. Megan Jones, Associate Mang. of Investor Relations
Mr. Tim Caprez, Chief Compliance Counsel & VP
Mr. Vic Parker, Head of Sales (LinkedIn Profile)

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

141 employees have rated Exact Sciences CEO Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among Exact Sciences' employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Exact Sciences' key competitors?

Some companies that are related to Exact Sciences include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of EXAS's competitors.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), PayPal (PYPL), Square (SQ), Advanced Micro Devices (AMD), The Walt Disney (DIS) and AbbVie (ABBV).

What is Exact Sciences' stock symbol?

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Who are Exact Sciences' major shareholders?

Exact Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (10.66%), ARK Investment Management LLC (5.33%), Baillie Gifford & Co. (2.54%), Artisan Partners Limited Partnership (1.57%), Sumitomo Mitsui Trust Holdings Inc. (1.58%) and Nikko Asset Management Americas Inc. (1.30%). Company insiders that own Exact Sciences stock include G Bradley Cole, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Sarah Condella, Scott C Johnson and Torsten Hoof.
View institutional ownership trends for Exact Sciences.

Which major investors are selling Exact Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Renaissance Technologies LLC, Artisan Partners Limited Partnership, Eminence Capital LP, Nuveen Asset Management LLC, Wasatch Advisors Inc., Factory Mutual Insurance Co., and Worldquant Millennium Advisors LLC. Company insiders that have sold Exact Sciences company stock in the last year include Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Sarah Condella, and Torsten Hoof.
View insider buying and selling activity for Exact Sciences or view top insider-selling stocks.

Which major investors are buying Exact Sciences stock?

EXAS stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Baillie Gifford & Co., Price T Rowe Associates Inc. MD, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Perceptive Advisors LLC, Principal Financial Group Inc., and Principal Financial Group Inc..
View insider buying and selling activity for Exact Sciences or or view top insider-buying stocks.

How do I buy shares of Exact Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exact Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $125.01.

How much money does Exact Sciences make?

Exact Sciences has a market capitalization of $21.45 billion and generates $1.49 billion in revenue each year. The medical research company earns $-848,530,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

How many employees does Exact Sciences have?

Exact Sciences employs 5,000 workers across the globe.

When was Exact Sciences founded?

Exact Sciences was founded in 1995.

What is Exact Sciences' official website?

The official website for Exact Sciences is www.exactsciences.com.

Where are Exact Sciences' headquarters?

Exact Sciences is headquartered at 5505 ENDEAVOR LANE, MADISON WI, 53719.

How can I contact Exact Sciences?

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company can be reached via phone at 608-535-8815 or via email at [email protected]

This page was last updated on 6/14/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here